Sunday, October 4, 2026
25.6 C
Bengaluru

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview

The oncology sector remains the most dominant area in healthcare, with over 50% of ongoing clinical trials focused on cancer treatment. In 2023, the global oncology market was valued at $222.36 billion and is projected to reach $521.6 billion by 2033, growing at a CAGR of 8.9% from 2024 onward.

With personalized medicine, AI-driven drug discovery, and innovative treatment modalities shaping the landscape, big pharma, biotech startups, and investors are strategically positioning themselves to capitalize on these advancements.

2. Key Trends Shaping Oncology in 2025

Precision Medicine & Targeted Therapies

  • Advances in genomic profiling and biomarker-driven treatments are enabling personalized oncology care.
  • Liquid biopsy technologies and companion diagnostics are improving early detection and treatment selection.

Antibody-Drug Conjugates (ADCs) Take Center Stage

  • ADCs, which deliver chemotherapy directly to cancer cells, are becoming a key alternative to traditional chemotherapy.
  • Companies like Daiichi Sankyo, AstraZeneca, and Pfizer are aggressively expanding their ADC portfolios.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

Topics

spot_img

Related Articles

spot_imgspot_img